

Jette Lautrup Frederiksen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7976473/publications.pdf>

Version: 2024-02-01

48
papers

2,386
citations

361045

20
h-index

233125

45
g-index

48
all docs

48
docs citations

48
times ranked

2845
citing authors

#	ARTICLE	IF	CITATIONS
1	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology, The</i> , 2017, 16, 797-812.	4.9	397
2	2021 MAGNIMSâ€“CMSCâ€“NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology, The</i> , 2021, 20, 653-670.	4.9	302
3	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology, The</i> , 2018, 17, 405-415.	4.9	238
4	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2017, 16, 189-199.	4.9	210
5	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020, 16, 171-182.	4.9	150
6	Vaccines and multiple sclerosis: a systematic review. <i>Journal of Neurology</i> , 2017, 264, 1035-1050.	1.8	117
7	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.5	96
8	Optical coherence tomography in multiple sclerosis. <i>Eye</i> , 2018, 32, 884-888.	1.1	93
9	Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2017, 264, 1837-1853.	1.8	91
10	Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2018, 91, e2265-e2275.	1.5	84
11	Serial Visual Evoked Potentials in 90 Untreated Patients With Acute Optic Neuritis. <i>Survey of Ophthalmology</i> , 1999, 44, S54-S62.	1.7	67
12	Zinc in Multiple Sclerosis. <i>ASN Neuro</i> , 2016, 8, 175909141665151.	1.5	56
13	Epstein-Barr Virus and Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 587078.	2.2	52
14	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
15	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. <i>CNS Drugs</i> , 2018, 32, 1159-1171.	2.7	38
16	Current Evidence on the Efficacy of Gluten-Free Diets in Multiple Sclerosis, Psoriasis, Type 1 Diabetes and Autoimmune Thyroid Diseases. <i>Nutrients</i> , 2020, 12, 2316.	1.7	37
17	Comparative effectiveness of teriflunomide and dimethyl fumarate. <i>Neurology</i> , 2019, 92, e1811-e1820.	1.5	36
18	Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: A review. <i>Clinical Neurophysiology</i> , 2017, 128, 1234-1245.	0.7	35

#	ARTICLE	IF	CITATIONS
19	The association between multiple sclerosis and uveitis. <i>Survey of Ophthalmology</i> , 2017, 62, 89-95.	1.7	35
20	Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	32
21	The role of gluten in multiple sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 156-163.	0.9	21
22	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	1.4	21
23	Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 391-400.	1.4	14
24	Neurovascular contact plays no role in trigeminal neuralgia secondary to multiple sclerosis. <i>Cephalalgia</i> , 2021, 41, 593-603.	1.8	13
25	Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 263-277.	1.6	11
26	Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study). <i>Patient Preference and Adherence</i> , 2018, Volume 12, 569-575.	0.8	9
27	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	1.1	9
28	Fibrinogen: A potential biomarker for predicting disease severity in multiple sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102509.	0.9	8
29	The effectiveness of natalizumab vs fingolimod – A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	0.9	8
30	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
31	Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 2755-2763.	1.8	7
32	The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 3316-3324.	1.8	6
33	Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103891.	0.9	6
34	A free and simple computerized screening test for visual field defects. <i>Scandinavian Journal of Psychology</i> , 2019, 60, 289-294.	0.8	5
35	Assessment of Artificial Intelligence Automatic Multiple Sclerosis Lesion Delineation Tool for Clinical Use. <i>Clinical Neuroradiology</i> , 2022, 32, 643-653.	1.0	5
36	Reactivity of Rheumatoid Arthritis-Associated Citrulline-Dependent Antibodies to Epstein-Barr Virus Nuclear Antigen1-3. <i>Antibodies</i> , 2022, 11, 20.	1.2	5

#	ARTICLE	IF	CITATIONS
37	MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2022, 439, 120320.	0.3	5
38	Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis – A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 8, 93-95.	0.9	4
39	Specificity of Anti-Citrullinated Protein Antibodies to Citrullinated $\hat{\pm}$ -Enolase Peptides as a Function of Epitope Structure and Composition. <i>Antibodies</i> , 2021, 10, 27.	1.2	4
40	PCR typing of DNA fragments of the two short tandem repeat (STR) systems upstream of the human myelin basic protein (MBP) gene in Danes and Greenland Eskimos. <i>Forensic Science International</i> , 1996, 78, 139-156.	1.3	3
41	Functional – structural assessment of the optic pathways in patients with optic neuritis. <i>Documenta Ophthalmologica</i> , 2020, 140, 159-168.	1.0	3
42	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. <i>NeuroImage: Clinical</i> , 2021, 30, 102659.	1.4	3
43	DETECTION OF ANTIBODIES TO THE 20S PROTEASOME BY ELISA. <i>Journal of Immunoassay and Immunochemistry</i> , 2013, 34, 384-392.	0.5	1
44	Sensitive Assessment of Acute Optic Neuritis by a New, Digital Flicker Test. <i>Ophthalmic Research</i> , 2020, 63, 332-340.	1.0	1
45	Multifocal visual evoked potential evaluation for diagnosis of acute optic neuritis and for prediction of visual outcome and ganglion cell layer thinning following optic neuritis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1717-1726.	1.4	1
46	Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2019, 93, 723-723.	1.5	0
47	Reader response: Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study. <i>Neurology</i> , 2020, 94, 1048-1049.	1.5	0
48	Anti-myelin oligodendrocyte glycoprotein antibodies in a girl with good recovery after five episodes of prior idiopathic optic neuritis. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 22, 101060.	0.4	0